• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过胶原蛋白圆盘递送眼部阿昔洛韦:一种用于筛选抗病毒药物的小鼠模型。

Ocular acyclovir delivery by collagen discs: a mouse model to screen anti-viral agents.

作者信息

Willey D E, Williams I, Faucett C, Openshaw H

机构信息

Department of Neurology, City of Hope National Medical Center, Duarte, CA 91010.

出版信息

Curr Eye Res. 1991;10 Suppl:167-9. doi: 10.3109/02713689109020374.

DOI:10.3109/02713689109020374
PMID:1650665
Abstract

Discs 1.6 mm in diameter trephined from corneal collagen shields were used to deliver acyclovir (ACV) to the cornea of mice inoculated with herpes simplex virus type 1 (HSV-1). In the first minute after application to the cornea, there was a 23% decrease of ACV in the discs. After the first minute, ACV clearance from the discs appeared to be exponential with a half-life of 21 minutes. Treatment given 3 times a day reduced HSV-1 titer in tear film, corneal tissue, and trigeminal ganglia. This animal model should be useful to conserve novel potential anti-viral drugs undergoing initial screening.

摘要

从角膜胶原盾上切下直径1.6毫米的圆盘用于将阿昔洛韦(ACV)递送至接种单纯疱疹病毒1型(HSV-1)的小鼠角膜。应用于角膜后的第一分钟内,圆盘中的阿昔洛韦减少了23%。第一分钟后,阿昔洛韦从圆盘中的清除似乎呈指数关系,半衰期为21分钟。一天给药3次可降低泪膜、角膜组织和三叉神经节中的HSV-1滴度。这种动物模型对于保存正在进行初步筛选的新型潜在抗病毒药物应该是有用的。

相似文献

1
Ocular acyclovir delivery by collagen discs: a mouse model to screen anti-viral agents.通过胶原蛋白圆盘递送眼部阿昔洛韦:一种用于筛选抗病毒药物的小鼠模型。
Curr Eye Res. 1991;10 Suppl:167-9. doi: 10.3109/02713689109020374.
2
Use of collagen shields in the treatment of herpetic keratitis.胶原盾在疱疹性角膜炎治疗中的应用。
Curr Eye Res. 1991;10 Suppl:189-91. doi: 10.3109/02713689109020378.
3
Effect of oral valaciclovir on herpetic keratitis.口服伐昔洛韦对疱疹性角膜炎的影响。
Cornea. 2006 Dec;25(10 Suppl 1):S64-7. doi: 10.1097/01.ico.0000247216.08886.9d.
4
Effect of intensive acyclovir therapy during artificial reactivation of latent herpes simplex virus.潜伏性单纯疱疹病毒人工激活期间阿昔洛韦强化治疗的效果
Proc Soc Exp Biol Med. 1983 Mar;172(3):316-23. doi: 10.3181/00379727-172-41563.
5
Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea.9-(1,3-二羟基-2-丙氧基甲基)鸟嘌呤(DHPG)对兔角膜单纯疱疹病毒(HSV)的抑制作用
Curr Eye Res. 1987 Jan;6(1):241-5. doi: 10.3109/02713688709020098.
6
Evaluation of the antiherpetic activity of acyclovir in rabbits.
Am J Med. 1982 Jul 20;73(1A):155-60. doi: 10.1016/0002-9343(82)90082-1.
7
Effect of acyclovir on thermal stress-induced herpesvirus reactivation.阿昔洛韦对热应激诱导的疱疹病毒再激活的影响。
Curr Eye Res. 2004 Aug-Sep;29(2-3):137-44. doi: 10.1080/02713680490504560.
8
Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.评估抗病毒药物局部疗效的新型动物模型:阿昔洛韦治疗无毛小鼠皮肤单纯疱疹病毒1型(HSV-1)感染时的通量与疗效相关性
Pharm Res. 1992 Aug;9(8):979-89. doi: 10.1023/a:1015838007864.
9
Effects of acyclovir therapy during simultaneous reactivation of latent HSV-1 in rabbits.阿昔洛韦疗法对兔潜伏性单纯疱疹病毒1型同时再激活的影响。
Antiviral Res. 1987 May;7(4):237-43. doi: 10.1016/0166-3542(87)90032-5.
10
In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model.二肽阿昔洛韦前药缬氨酸-缬氨酸-阿昔洛韦在兔眼模型中对单纯疱疹病毒1型上皮性和基质性角膜炎的体内抗病毒疗效。
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2529-34. doi: 10.1167/iovs.02-1251.

引用本文的文献

1
Synthetic and Natural Biomaterials in Veterinary Medicine and Ophthalmology: A Review of Clinical Cases and Experimental Studies.兽医学与眼科学中的合成与天然生物材料:临床病例与实验研究综述
Vet Sci. 2024 Aug 12;11(8):368. doi: 10.3390/vetsci11080368.
2
Antifungal drug ciclopirox olamine reduces HSV-1 replication and disease in mice.环吡酮胺抗真菌药物可减少小鼠体内 HSV-1 的复制和疾病。
Antiviral Res. 2018 Aug;156:102-106. doi: 10.1016/j.antiviral.2018.06.010. Epub 2018 Jun 15.